FY2025 EPS Estimates for SPRY Lowered by Cantor Fitzgerald

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of ARS Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($1.21) for the year, down from their previous forecast of ($1.02). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

Other equities research analysts have also issued reports about the stock. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Scotiabank assumed coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Raymond James boosted their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 14th. Oppenheimer initiated coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Leerink Partners boosted their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $31.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY opened at $12.63 on Wednesday. The firm’s 50 day simple moving average is $12.15 and its 200 day simple moving average is $13.07. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -24.76 and a beta of 1.03.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. The trade was a 56.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Laura Shawver sold 50,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 159,600 shares of company stock valued at $1,866,516 in the last 90 days. 40.10% of the stock is currently owned by company insiders.

Institutional Trading of ARS Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of SPRY. Wellington Management Group LLP grew its stake in ARS Pharmaceuticals by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 163,252 shares of the company’s stock valued at $1,722,000 after purchasing an additional 917 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of ARS Pharmaceuticals by 2.9% in the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock valued at $687,000 after buying an additional 1,824 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $217,000 after buying an additional 1,962 shares in the last quarter. Mariner LLC increased its holdings in ARS Pharmaceuticals by 5.8% during the fourth quarter. Mariner LLC now owns 35,908 shares of the company’s stock worth $379,000 after buying an additional 1,972 shares during the last quarter. Finally, LPL Financial LLC increased its holdings in ARS Pharmaceuticals by 11.4% during the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company’s stock worth $226,000 after buying an additional 2,190 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.